NCT07175220View on ClinicalTrials.gov

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

SHR2554; SHR-A2102

SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days

DRUG

SHR2554; Adabelimumab

SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days

DRUG

SHR2554; SHR-1701

SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY